Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01222299 · ClinicalTrials.gov registry record · Phase 1
Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber
A Phase 1 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 89
- Enrollment target
NCT01222299 is a Phase 1 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 89 participants.
The verdict
NCT01222299, a Phase 1 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 89 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety and efficacy of bepotastine besilate nasal product in seasonal allergic rhinitis patients.
Interventions
- DRUG bepotastine besilate nasal product - low dose
- DRUG bepotastine besilate nasal product - medium dose
- DRUG bepotastine besilate nasal product - high dose
- DRUG placebo comparator nasal product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2010-05 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01222299
The ClinicalTrials.gov registry entry for NCT01222299 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which bepotastine besilate nasal product - low dose is the first listed.
NCT01222299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01222299 about?
NCT01222299 is a clinical study titled "Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber". The purpose of this study is to examine the safety and efficacy of bepotastine besilate nasal product in seasonal allergic rhinitis patients.
What is the current status of trial NCT01222299?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 89 participants. The study started on 2010-05. Estimated completion is 2010-08.
What interventions are being tested in trial NCT01222299?
The interventions under investigation include: bepotastine besilate nasal product - low dose (DRUG), bepotastine besilate nasal product - medium dose (DRUG), bepotastine besilate nasal product - high dose (DRUG), placebo comparator nasal product (DRUG).
Who is sponsoring clinical trial NCT01222299?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.